Terms ending in 2038
Every in-force patent on Bold Limited's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,611,787 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | |
| US 11,040,993 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | |
| US 11,739,111 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | |
| US 12,415,825 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.